The Reporting of Harms in Randomized Controlled Trials of Hypertension Using the CONSORT Criteria for Harm Reporting

被引:23
作者
Bagul, Nitin Babulal [1 ]
Kirkham, Jamie J. [2 ]
机构
[1] Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England
[2] Univ Liverpool, Dept Biostat, Liverpool L69 3GS, Merseyside, England
关键词
harm; adverse event; CONSORT; CONSORT extension; drug safety; ADVERSE EVENTS; QUALITY; STATEMENT; IMPROVE;
D O I
10.3109/10641963.2012.681724
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to assess the quality of reporting of harms in hypertension clinical trials identified from the Cochrane Database using the Consolidated Standards of Reporting Trials (CONSORT) extension for harms reporting. Forty-one hypertension trials were included in the study. On average trials reported less than half of the items recommended by the CONSORT extension for harms (mean 9.83 items; 95% confidence interval 8.06, 11.60). Trialists need to address the perceived shortcomings in measurement, analysis, and reporting of harms data so that the available trial data can be considered as a balanced and reliable source of evidence.
引用
收藏
页码:548 / 554
页数:7
相关论文
共 18 条
[1]   Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].
Begg, C ;
Cho, M ;
Eastwood, S ;
Horton, R ;
Moher, D ;
Olkin, I ;
Pitkin, R ;
Rennie, D ;
Schulz, KF ;
Simel, D ;
Stroup, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639
[2]   Reporting of harms and adverse events in otolaryngology journals [J].
Bibawy, Haidy ;
Cossu, Anne ;
Cogan, Sophia ;
Rosenfeld, Richard .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2009, 140 (02) :241-244
[3]   Reporting of Harm in Randomized Controlled Trials Published in the Urological Literature [J].
Breau, Rodney H. ;
Gaboury, Isabelle ;
Scales, Charles D., Jr. ;
Fesperman, Susan F. ;
Watterson, James D. ;
Dahm, Philipp .
JOURNAL OF UROLOGY, 2010, 183 (05) :1693-1697
[4]   Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review [J].
Chowers, Michal Y. ;
Gottesman, Bat Sheva ;
Leibovici, Leonard ;
Pielmeier, Ulrike ;
Andreassen, Steen ;
Paul, Mical .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) :239-250
[5]   Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease [J].
Ethgen, M ;
Boutron, I ;
Baron, G ;
Giraudeau, B ;
Sibilia, J ;
Ravaud, P .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (01) :20-25
[6]   Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention [J].
Ethgen, Morgane ;
Boutron, Isabelle ;
Steg, Philippe Gabriel ;
Roy, Carine ;
Ravaud, Philippe .
TRIALS, 2009, 10
[7]   The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry [J].
Han, Changsu ;
Kwak, Kyung-phil ;
Marks, David M. ;
Pae, Chi-Un ;
Wu, Li-Tzy ;
Bhatia, Karnal S. ;
Masand, Prakash S. ;
Patkar, Ashwin A. .
CONTEMPORARY CLINICAL TRIALS, 2009, 30 (02) :116-122
[8]   Better reporting of harms in randomized trials: An extension of the CONSORT statement [J].
Ioannidis, JPA ;
Evans, SJW ;
Gotzsche, PC ;
O'Neill, RT ;
Altman, DG ;
Schulz, K ;
Moher, D .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) :781-788
[9]   The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews [J].
Kirkham, Jamie J. ;
Dwan, Kerry M. ;
Altman, Douglas G. ;
Gamble, Carrol ;
Dodd, Susanna ;
Smyth, Rebecca ;
Williamson, Paula R. .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 :637-640
[10]  
Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3